Cargando…
P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429236/ http://dx.doi.org/10.1097/01.HS9.0000969572.68411.a2 |
| _version_ | 1785090661071978496 |
|---|---|
| author | Paolo Maria Zambrotta, Giovanni Assouline, Sarit Nicolini, Franck E. Abruzzese, Elisabetta Pungolino, Ester Cristina Miggiano, Maria Elena, Chiara Alvarez Larran, Alberto Triguero Moreno, Ana Iurlo, Alessandra Bucelli, Cristina Lunghi, Francesca Capodanno, Isabella Maffioli, Margherita Galimberti, Sara Caocci, Giovanni Stagno, Fabio Saussele, Susanne Fava, Carmen Le Coutre, Philipp Bonifacio, Massimiliano Guglielmana, Veronica Colombo, Federica Antolinni, Laura Gambacorti-Passerini, Carlo |
| author_facet | Paolo Maria Zambrotta, Giovanni Assouline, Sarit Nicolini, Franck E. Abruzzese, Elisabetta Pungolino, Ester Cristina Miggiano, Maria Elena, Chiara Alvarez Larran, Alberto Triguero Moreno, Ana Iurlo, Alessandra Bucelli, Cristina Lunghi, Francesca Capodanno, Isabella Maffioli, Margherita Galimberti, Sara Caocci, Giovanni Stagno, Fabio Saussele, Susanne Fava, Carmen Le Coutre, Philipp Bonifacio, Massimiliano Guglielmana, Veronica Colombo, Federica Antolinni, Laura Gambacorti-Passerini, Carlo |
| author_sort | Paolo Maria Zambrotta, Giovanni |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10429236 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104292362023-08-17 P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY Paolo Maria Zambrotta, Giovanni Assouline, Sarit Nicolini, Franck E. Abruzzese, Elisabetta Pungolino, Ester Cristina Miggiano, Maria Elena, Chiara Alvarez Larran, Alberto Triguero Moreno, Ana Iurlo, Alessandra Bucelli, Cristina Lunghi, Francesca Capodanno, Isabella Maffioli, Margherita Galimberti, Sara Caocci, Giovanni Stagno, Fabio Saussele, Susanne Fava, Carmen Le Coutre, Philipp Bonifacio, Massimiliano Guglielmana, Veronica Colombo, Federica Antolinni, Laura Gambacorti-Passerini, Carlo Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429236/ http://dx.doi.org/10.1097/01.HS9.0000969572.68411.a2 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Paolo Maria Zambrotta, Giovanni Assouline, Sarit Nicolini, Franck E. Abruzzese, Elisabetta Pungolino, Ester Cristina Miggiano, Maria Elena, Chiara Alvarez Larran, Alberto Triguero Moreno, Ana Iurlo, Alessandra Bucelli, Cristina Lunghi, Francesca Capodanno, Isabella Maffioli, Margherita Galimberti, Sara Caocci, Giovanni Stagno, Fabio Saussele, Susanne Fava, Carmen Le Coutre, Philipp Bonifacio, Massimiliano Guglielmana, Veronica Colombo, Federica Antolinni, Laura Gambacorti-Passerini, Carlo P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY |
| title | P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY |
| title_full | P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY |
| title_fullStr | P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY |
| title_full_unstemmed | P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY |
| title_short | P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY |
| title_sort | p667: risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: final analysis of the tfr-pro study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429236/ http://dx.doi.org/10.1097/01.HS9.0000969572.68411.a2 |
| work_keys_str_mv | AT paolomariazambrottagiovanni p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT assoulinesarit p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT nicolinifrancke p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT abruzzeseelisabetta p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT pungolinoester p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT cristinamiggianomaria p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT elenachiara p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT alvarezlarranalberto p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT trigueromorenoana p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT iurloalessandra p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT bucellicristina p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT lunghifrancesca p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT capodannoisabella p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT maffiolimargherita p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT galimbertisara p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT caoccigiovanni p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT stagnofabio p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT sausselesusanne p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT favacarmen p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT lecoutrephilipp p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT bonifaciomassimiliano p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT guglielmanaveronica p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT colombofederica p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT antolinnilaura p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy AT gambacortipasserinicarlo p667riskofprogressioninchronicphasechronicmyeloidleukemiapatientseligiblefortyrosinekinaseinhibitordiscontinuationfinalanalysisofthetfrprostudy |